


RESEARCH ARTICLE

Linking Tumor Mutations to Drug Responses via a Quantitative Chemical–Genetic Interaction Map

Maria M. Martins¹, Alicia Y. Zhou¹, Alexandra Corella¹, Dai Horiuchi¹, Christina Yau¹, Taha Rakshandehroo¹, John D. Gordan¹, Rebecca S. Levin¹, Jeff Johnson¹, John Jascur¹, Mike Shales¹, Antonio Sorrentino¹, Jaime Cheah², Paul A. Clemons², Alykhan F. Shamji², Stuart L. Schreiber^{2,3}, Nevan J. Krogan¹, Kevan M. Shokat^{1,3}, Frank McCormick¹, Andrei Goga¹, and Sourav Bandyopadhyay¹



ABSTRACT

There is an urgent need in oncology to link molecular aberrations in tumors with therapeutics that can be administered in a personalized fashion. One approach identifies synthetic-lethal genetic interactions or dependencies that cancer cells acquire in the presence of specific mutations. Using engineered isogenic cells, we generated a systematic and quantitative chemical-genetic interaction map that charts the influence of 51 aberrant cancer genes on 90 drug responses. The dataset strongly predicts drug responses found in cancer cell line collections, indicating that isogenic cells can model complex cellular contexts. Applying this dataset to triple-negative breast cancer, we report clinically actionable interactions with the *MYC* oncogene, including resistance to AKT-PI3K pathway inhibitors and an unexpected sensitivity to dasatinib through LYN inhibition in a synthetic lethal manner, providing new drug and biomarker pairs for clinical investigation. This scalable approach enables the prediction of drug responses from patient data and can accelerate the development of new genotype-directed therapies.

SIGNIFICANCE: Determining how the plethora of genomic abnormalities that exist within a given tumor cell affects drug responses remains a major challenge in oncology. Here, we develop a new mapping approach to connect cancer genotypes to drug responses using engineered isogenic cell lines and demonstrate how the resulting dataset can guide clinical interrogation. *Cancer Discov*; 5(2); 154-67. ©2014 AACR.

INTRODUCTION

Recent advances in sequencing technology have led to a dramatic increase in the discovery of altered genes in patient tumors. This rapid accumulation of genetic information has led to a bottleneck at the level of understanding of the functional and therapeutic implications of aberrant gene activities in cancer (1). The pressing clinical need to identify therapeutic biomarkers has spurred several large-scale screening efforts using genomically characterized cancer cell line collections to identify molecular correlates of drug responses (2-4). Although these collections reflect the diversity of mutations found in human tumors, each cell line carries mutational “baggage” in the form of hundreds to thousands of different genomic alterations. This makes it difficult to link drug responses with the presence of a single causal mutation. In addition, rare mutations that occur with low frequency may not be adequately represented in cancer cell line collections. Therefore, new sensitive and scalable approaches to model genetic aberrations are required to address these emerging challenges in oncology.

¹University of California, San Francisco, San Francisco, California. ²Center for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts. ³Howard Hughes Medical Institute, Bethesda, Maryland.

Note: Supplementary data for this article are available at Cancer Discovery Online (<http://cancerdiscovery.aacrjournals.org/>).

M.M. Martins and A.Y. Zhou contributed equally to this article.

Corresponding Authors: Sourav Bandyopadhyay, University of California, San Francisco, 1450 3rd Street, MC 0520, San Francisco, CA 94158-9001. Phone: 415-4763425; E-mail: bandyopadhyays@cc.ucsf.edu; and Andrei Goga, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143. E-mail: andrei.goga@ucsf.edu

doi: 10.1158/2159-8290.CD-14-0552

©2014 American Association for Cancer Research.

Another challenge for the development of personal cancer therapies is the lack of direct therapeutic approaches for many oncogenes, such as transcription factors or other non-kinase targets. In these cases, an especially useful alternative method to identify potential therapeutic liabilities is through a synthetic lethal approach. This strategy identifies interactions between mutant genes and inhibition of alternative pathways using functional genomics (5, 6). This framework exploits mutational changes in cells that result in a dependence on pathways that are otherwise non-essential. In lower organisms, systematic genetic interaction maps have transformed our understanding of basic biologic processes and drug responses (7, 8). In mammals, synthetic lethal screens using RNAi or small molecules have identified several vulnerabilities in *RAS*-mutated cell lines (9-15). Previous work has shown that isogenic cell lines can be used to explore therapeutic responses for candidate inhibitors (16-19). However, this approach has not yet been applied in a systematic and quantitative fashion that is able to measure both resistance and sensitivity. Here, we apply a systematic approach to determine the degree to which isogenic lines can serve as a starting point to map chemical-genetic interactions and identify novel therapeutic strategies in oncology.

Breast cancer has served as a prime example for biomarker-driven therapy. Several targeted therapies are now given as standard-of-care for patients who present with the overexpression of the human epidermal growth factor receptor 2 (HER2/ERBB2) or the estrogen and progesterone receptors. However, no biomarker-driven therapy is available to treat the most aggressive and challenging receptor triple-negative breast cancer (TNBC) subtype. Previous studies have shown that the transcription factor *MYC* is a breast cancer oncoprotein and plays an important functional role in TNBC (20-22). In The Cancer Genome Atlas (TCGA) study of

breast cancer, *MYC* was found to be focally amplified in 40% of TNBCs, and a *MYC* transcriptional signature was significantly upregulated in these tumors (23). Several early transgenic mouse models have shown that specific expression of *MYC* in the mammary gland by itself (24) or with cooperating oncogenes induces mammary tumor formation (25, 26). A conditional mouse model system subsequently demonstrated that *MYC* is a true driver of mammary tumorigenesis by showing that tumor formation regressed completely upon *MYC* withdrawal (27). More recent studies have shown that inhibition of endogenous *MYC* by a dominant-negative *MYC* mutant can attenuate tumor formation in lung and pancreatic cancer mouse models driven by other oncogenes (28, 29). In an osteogenic sarcoma *MYC*-driven mouse model, even transient inactivation of *MYC* induced sustained tumor regression, indicating the potential efficacy for *MYC*-inhibitory therapies (30). These studies together clearly demonstrate that *MYC* is an important therapeutic target for cancer tumorigenesis. However, despite this enthusiasm, specific small-molecule inhibitors of *MYC* have yet to be translated into clinically viable therapies for patients. Recently, efforts to target upstream regulation of *MYC* by BET bromodomain inhibitors have shown dramatic effects in some *MYC*-driven hematopoietic cancers (31). However, whether *MYC* is the key target of such inhibitors in solid tumors is still unclear (32). Hence, there is a great need to target *MYC* indirectly, and several studies have used synthetic lethal strategies to exploit *MYC* overexpression in breast, lung, and liver cancers (17, 33–36). These studies have led to the identification of a diverse set of candidates, including cyclin-dependent kinases (CDK1), Aurora kinases, SUMO-activating enzymes (SAE1/2), and casein kinase (CSNK1E), which could point to a dependency on DNA repair and cell-cycle checkpoints in cells with high *MYC* expression (37). Although CDK1 and Aurora kinases may be pharmacologically tractable targets, currently no inhibitors of these molecules have been approved for use in TNBC.

To aid in the development of new synthetic lethal strategies, we have developed an interaction mapping strategy using isogenic cell lines to measure direct relationships between expression of cancer-associated genes and the proliferative response to clinically relevant compounds. We show that this dataset is highly complementary to drug responses found by profiling tumor cell line collections that are an order of magnitude larger. Furthermore, we demonstrate ways in which these data could aid in the design of new personalized clinical trials. In particular, these data identify a novel synthetic lethal relationship between expression of the *MYC* proto-oncogene and sensitivity to the multikinase inhibitor dasatinib, providing a novel application for an already FDA-approved drug and an associated biomarker for clinical interrogation.

RESULTS

Creation of a Quantitative Chemical–Genetic Interaction Map

We developed a chemical–genetic interaction mapping strategy to uncover the impact of expression of specific genes on proliferative responses to a panel of emerging and estab-

lished therapeutics (Fig. 1A). To study the impact of aberrant gene activity in isolation, we developed an isogenic model of TNBC using the receptor-negative, nontumorigenic cell line MCF10A. This epithelial cell line is derived from healthy breast tissue and is diploid and largely devoid of somatic alterations (38). Importantly, MCF10A cells are amenable to transformation by a wide variety of oncogenes, making them an appropriate cell type to study diverse oncogene signaling pathways (38). We created 51 stable cell lines by ectopic expression of wild-type and mutant genes that are common in breast and other cancers to model the impact of recurrent gene mutation, amplification, and overexpression (Supplementary Table S1 and Supplementary Fig. S1A). Gene expression was confirmed via immunoblot and some of the genes tested were able to promote growth factor independence and anchorage-independent growth, indicating the capacity for transformation (Supplementary Table S1 and Supplementary Fig. S1B and S1C).

The majority of current cancer drugs have not been linked to specific genomic alterations that could be used as biomarkers to specify their selective therapeutic efficacy. To measure the impact of gene activation on cellular responses systematically, we screened our isogenic panel against a library of 90 anticancer therapeutics spanning multiple stages of clinical development. Seventy-nine percent of these drugs have already been through at least one clinical trial, and 25% are already FDA-approved compounds (Supplementary Table S2 and Fig. 1B). Together, they target a broad variety of canonical cancer pathways and targets (Fig. 1C). We developed a robust screening method to quantitatively assess the impact of gene expression on drug responses. In this screen, isogenic cells expressing control vector or a gene of interest are plated separately and their relative proliferation after 72 hours of drug treatment is compared by high-content microscopy. Cell numbers from each line and treatment are compared and the effect size is determined by the fold change in cell number at the IC_{50} as compared with control, averaged over replicates (Fig. 1D and Supplementary Methods). Next, the *P* value of significance is converted to a signed chemical–genetic interaction score (*S*). Positive *S* values indicate that the expression of the gene drove drug resistance, and negative *S* values indicate that the gene caused drug sensitivity as compared with vector controls. The screen displayed a high correlation of scores across replicates ($r = 0.618$; Supplementary Fig. S2A and S2B) and an empirical false-discovery rate (FDR) of 1% and 10% corresponding to score cutoffs of approximately $S = \pm 4$ and $S = \pm 2$, respectively (Supplementary Fig. S2C). Notably, these numbers compare favorably with similar screens performed in yeast (39). Altogether, we determined quantitative scores for 4,541 gene–drug interactions and identified 174 resistance interactions and 97 sensitivity interactions at $S = \pm 2$, corresponding to a 10% FDR (Supplementary Table S3).

As a control, we examined the impact of activating G12V mutations in the *RAS* family of oncogenes (*HRAS*, *KRAS*, and *NRAS*) on drug responses that drove resistance to multiple EGFR inhibitors, including erlotinib and vandetanib (Fig. 1D). It is well established that *KRAS* operates downstream of EGFR, and our results are consistent with this known relationship. In addition, our results confirm findings




Figure 1. An isogenic cell line screen reveals genomic drivers of drug response. **A**, overview of screening approach in MCF10A isogenic cell lines. For each isogenic line, relative drug responses are comparing empty vector expressing MCF10A cells exposed to the same drugs. **B**, pie chart depicting FDA approval status of 90 compounds in this study. **C**, distribution of drugs targeting distinct cancer pathways and particular kinase targets (inset). **D**, volcano plot comparing magnitude and significance score of altered drug responses as compared against control MCF10A parental cells for 4,541 chemical-genetic interactions interrogated in this study. Maximum FDR rates of score ranges are indicated (see Methods). Data points reflecting resistance compared with control of *HRAS*/*KRAS*/*NRAS* G12V-mutant MCF10A cells to EGFR inhibitors erlotinib and vandetanib are highlighted. **E**, the 51 genes analyzed in this study are sorted on the basis of the number of high scoring chemical interactions (number of interactions with $|S| > 4$ or $|S| > 2$).

from other cancer cell line drug screens and clinical observations that indicate *KRAS* mutations can drive acquired resistance to EGFR inhibitors in patients (2, 40). A number of other activated oncoproteins also induced resistance to erlotinib, including the TPR-MET fusion ($S = 4.3$), IGF1R ($S = 3.4$), BRAF^{V600E} ($S = 2.1$), and constitutively active MEK (MEKDD; $S = 4.4$), delineating several routes of resistance to EGFR inhibitor therapy, most of which have been observed in the clinic (Supplementary Fig. S2D; refs. 41–43). These results were largely consistent with other EGFR inhibitors, including BIBW-2992 (Supplementary Fig. S2E). We also observed that cells expressing a common activating mutation in *PIK3CA* (H1047R) were resistant to MEK inhibitors AZD-6244 ($S = 2.1$) and CI-1040 ($S = 3.1$), reflecting known redundancy between PI3K and MEK pathways. As MEK inhibitor clinical trials are ongoing, these observations support emerging data that patients with activating *PIK3CA* mutations are not likely to respond to this therapeutic approach (44) and predict that *PIK3CA* mutation may drive acquired resistance to MEK inhibitors. In addition, expected drug sensitivities between kinases and drugs that directly target them were identified,

including expression of EGFR, which led to sensitivity to the EGFR inhibitor gefitinib ($S = -2.8$), and activation of the AKT pathway by myristoylated AKT (MYR-AKT), which led to sensitivity to the PI3K/mTOR inhibitor BEZ-235 ($S = -3.5$). We also identified the PLK inhibitor BI-3536 as the top synthetic lethal hit with *RAS* genes (*HRAS*, *KRAS*, *NRAS* mean $S = -2.0$), confirming a previous synthetic lethal RNAi screen that identified PLK1 dependency and mitotic stress as a hallmark of the *RAS* oncogenic state (10). Among the 51 genes in this study, *RAS*-family oncogenes altered the most drug responses. This highlights their importance in the selection of drug-treatment regimens, especially because they are among the most mutated genes in human cancer (Fig. 1E). Analysis of the mutational spectrum of breast cancers also revealed that many less-frequently altered genes can modulate the response to a large number of compounds, providing a rationale for their consideration as cancer targets and modifiers of clinical responses (Supplementary Fig. S2F). Thus, the resulting map highlights known drug responses driven by gene activation and provides a roadmap for the exploration of novel molecular drivers of therapeutic responses.




Figure 2. Global analysis of the chemical-genetic interaction map. **A**, comparison of chemical-genetic interactions from this study at a variety of significance cutoffs with 489 drug-gene associations spanning 21 genes and 40 drugs identified in the Cancer Genome Project (CGP) study through regression analysis (P value of 0.05; ref. 4). The score cutoff reflects the absolute value of the S -score, and therefore encapsulates both resistance and sensitivity. Dotted line represents background probability of overlap. **B**, a genetic interaction profile for each drug is calculated across 51 cell lines. Using a sliding cutoff based on correlation of profiles, the similarity of genetic interaction profiles for two drugs is plotted against the fraction of these drugs that have the same annotated molecular target. **C**, hierarchical clustering of drug profile similarities for compounds targeting multiple distinct biologic pathways.

Prediction of Cancer Cell Line Responses and Drug Similarities

The ability of isogenic cell line screens to recapitulate known clinical and cellular drug responses raises the possibility that they could complement cancer cell line screens of therapeutics, an established paradigm for biomarker identification. Recent screens have used regression techniques to identify molecular markers correlated with drug responses (2, 4). Comparison of the 21 genes and 40 drugs in common with the Cancer Genome Project (CGP) study (4) revealed a strong degree of overlap between drug responses using isogenic lines and responses found to be significantly correlated with genotypes in the CGP study. Reflecting the quantitative nature of our dataset, this overlap was related to the S -score cutoff used to define hits (more than 50% at $|S| > 4.5$; Fig. 2A) and was strongly significant at a variety of cutoffs ($P = 1.4 \times 10^{-5}$ at $|S| > 2.5$; Supplementary Fig. S3). Thus, our approach complements cancer cell line screening and provides a quantitative basis for the prediction of genotype-specific dependencies that can be explored in other established model systems.

Existing drugs target a limited number of pathways and can have unexpected but significant off-target effects that dominate their biologic activities. To identify the degree to which off-target effects dominate the chemical-genetic interaction map, we asked whether independent small molecules targeting the same pathway have a similar spectrum of genetic interactions. We used the profile of interactions for a given drug across the isogenic panel to provide a sensitive phenotypic signature and evaluated the degree to which this profile was shared between drugs. We found that independent drugs with the same annotated molecular target had a highly correlated profile that was predictive of the probability that they targeted the same pathway (Fig. 2B). Furthermore, drugs targeting the same pathways had highly similar profiles that were distinct from other classes of inhibitors (Fig. 2C), suggesting that their cellular

effects are primarily through inhibition of the intended molecular target. These data indicate that the interaction map has the ability to link novel compounds to existing classes of drugs and serve as a platform for exploring drug mechanism of action.

New Pharmacologically Tractable Dependencies of the MYC Oncogene

A powerful use of the chemical-genetic interaction map is to identify synthetic lethal relationships involving oncogene encoding proteins for which no specific small-molecule inhibitors exist and are thus considered undruggable. One such oncogene, the transcription factor gene *MYC*, is among the most frequently amplified genes in breast cancer and associated with the basal molecular or TNBC pathologic subtype, the most aggressive form of breast cancer (23, 33). Previous synthetic lethal approaches centered on *MYC* have identified several new genes that have not yet been easily targeted pharmacologically (34, 35, 45, 46). Therefore, we interrogated the chemical-genetic interaction map to identify existing, clinically relevant small molecules that can modulate the response of cells overexpressing *MYC*. We uncovered that *MYC* drove resistance to six distinct AKT-PI3K-mTOR pathway inhibitors, most strongly with the AKT inhibitor MK-2206 ($S = 4.5$; Fig. 3A). In validation studies, all six inhibitors significantly inhibited the relative proliferation of control MCF10A^{PUR0} cells while leaving MCF10A^{MYC} cells unaffected (Fig. 3B). Mining previously published gene expression and drug-response data, we found that increased *MYC* expression could significantly predict resistance to MK-2206 in a panel of 20 breast cancer cell lines ($P = 0.01$), further indicating strong corroboration between isogenic and cancer cell line responses (Fig. 3C). These data are consistent with prior reports of *MYC*-driven resistance to other PI3K pathway inhibitors in cell lines (18) and mouse models (47). Together, these results shed light on previous data suggesting that AKT-PI3K inhibitors are not effective in the basal breast cancer molecular




Figure 3. Validation of MYC-driven drug responses. **A**, volcano plot of MYC-driven drug responses identified in MCF10A^{MYC} cells versus control. Drug responses with $S \geq 2$ are highlighted. **B**, validation of relative growth rates of drug-treated MCF10A^{PURO} and MCF10A^{MYC} cells compared with DMSO control in the presence of AKT-PI3K-MTOR pathway inhibitors as indicated in **A**. **C**, sensitivity to AKT inhibitor MK-2206 compared with MYC expression across a panel of 20 breast cancer cell lines separated into two equally sized groups to define sensitive and resistant lines with RNAseq data from ref. 54. **D**, validation of relative growth rates of drug-treated MCF10A lines with synthetic lethal hits in **A**. **E**, concentration-response of viability of isogenic cell lines to GSK3 β inhibitor CHIR-99021. **F**, fraction of total cell population undergoing apoptosis in response to drug treatment for 24 hours as measured by Annexin V staining. **G**, levels of p-GSK3 β Ser9 and total MYC after treatment of MCF10A cells for 18 hours. GAPDH is used as a loading control. Unless otherwise noted, drug concentrations are the near IC_{50} listed in Supplementary Table S2. ***, $P < 0.001$; **, $P < 0.01$.

subtype (48), where MYC expression is known to be high (23, 33). Because a number of similar compounds are approved or under investigation in breast cancer, we hypothesize that MYC status may be a useful criterion for exclusion of patients from trials involving these inhibitors.

Several strong synthetic lethal interactions pointed us toward new therapies that might be effective against tumors harboring high levels of MYC (Fig. 3A). Detailed analysis of three top candidates, BI-6727 (PLK inhibitor), CHIR-99021 (GSK3 β inhibitor), and dasatinib (ABL and SRC-family kinase inhibitor), revealed that all drugs were significantly more effective in a MYC-dependent manner in MCF10A cells (Fig. 3D). Sensitivity to BI-6727 ($S = -2.5$), a PLK inhibitor that targets the mitotic machinery, is consistent with previous reports that inhibitors of related mitotic kinases have been shown to have preferential activity in MYC-high cancers (17, 36). Likewise, the CDK inhibitor flavopiridol ($S = -1.55$), the kinesin inhibitor SB743921 ($S = -1.55$), as well as a structurally distinct PLK inhibitor BI2536 ($S = -1.47$), scored negatively with MYC, indicating that MYC expression leads to an increased dependence on multiple mitotic processes.

An RNAi screen previously identified depletion of GSK3 β as synthetic lethal with MYC (35), but a small molecule that can phenocopy knockdown of GSK3 β had not yet been identified. We found that MYC expression resulted in cellular sensitivity to CHIR-99021 through a reduction in cell viability (Fig. 3E), and induction of apoptosis in a MYC-dependent manner (Fig. 3F), confirming a synthetic lethal relationship. CHIR-99021 ($S = -2.6$) targets GSK3 β , which phosphorylates MYC to promote its degradation (49). Indicating an on-target effect, the cellular response to CHIR-99021 resulted in potent phospho-GSK3 β kinase inhibition and an increase in MYC protein, consistent with an increase in stability due to loss

of GSK3 β activity (Fig. 3G). Aberrant activation of MYC has been shown to induce apoptosis in a variety of model systems and therefore it is plausible that CHIR-99021 induces apoptosis through an increase in MYC activity (50). Although more work is required to further explore its utility in preclinical systems, we hypothesize that CHIR-99021 or other GSK3 β inhibitors that are currently in trials for neurodegenerative disorders (51) could potentially be repurposed for use in MYC-driven cancers.

Dasatinib Treatment Is Synthetic Lethal with MYC Activation in TNBC Model Systems

Mapping of synthetic lethal interactions with already FDA-approved inhibitors can lead to the discovery of previously unknown connections and can ultimately accelerate new clinical trials by repurposing clinically viable drugs. The strongest MYC synthetic lethal interaction was with dasatinib (Sprycel; $S = -3.0$), a tyrosine kinase inhibitor that is approved for use in BCR-ABL⁺ chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) with known off-target activities, including inhibition of the SRC-family kinases and ephrin kinases. Analysis across a range of concentrations revealed a specific reduction of cell number in MCF10A^{MYC} cells compared with controls after dasatinib treatment for 3 days (Fig. 4A). We also confirmed MYC-specific sensitivity using an orthogonal FACS-based competition assay in which MCF10A^{PURO} cells outcompeted their MYC counterparts over a range of dasatinib concentrations (Supplementary Fig. S4A). The parental MCF10A cells contain a copy-number gain of the MYC locus presumably acquired during the immortalization process (38, 52). To model a more MYC-naïve state, we used a model system based on




Figure 4. MYC is synthetic lethal with dasatinib in engineered cell lines. **A**, relative proliferation of MCF10A^{PURO} versus MCF10A^{MYC} cell lines to a range of dasatinib concentrations. **B**, relative viability of HMEC MYC-ER cells treated with vehicle or 4-OHT to activate MYC in response to dasatinib for 48 hours. **C**, fraction of total cell population undergoing apoptosis in HMEC MYC-ER cells treated with vehicle or 4-OHT in the presence of dasatinib. **D**, response to dasatinib (250 nmol/L) in HMEC MYC-ER cells through measurement of molecular correlates of apoptosis including PARP cleavage and MCL1, BCL-XL, and BIM levels. Actin is a loading control. HMEC, human mammary epithelial cell.

primary human mammary epithelial cells (HMEC) that are derived from healthy breast tissue and have a limited lifespan and low MYC expression (53). We created a derivative of this cell line that constitutively expresses an inactive MYC-ER fusion protein that is activated in the presence of 4-hydroxy tamoxifen (4-OHT). HMEC cells in the presence of 4-OHT were 5-fold more sensitive to dasatinib (IC_{50} , ~200 nmol/L) as compared with vehicle-treated controls (IC_{50} , ~1 $\mu\text{mol/L}$; Fig. 4B). The sensitivity was matched by a significant 6-fold induction of apoptosis in cells with activated MYC versus controls ($P = 1 \times 10^{-7}$; Fig. 4C). Apoptosis was evidenced by PARP cleavage, attenuated expression of mitochondrial antiapoptotic markers MCL1 and BCL-XL, and induction of the proapoptotic BIM

tein (Fig. 4D and Supplementary Fig. S4B). Thus, cellular sensitivity in isogenic cell line model systems indicates that expression of MYC can drive a cytotoxic response to dasatinib in breast epithelial cells.

Dasatinib Has Preferential Activity in MYC-Expressing Cancer Cell Lines

Synthetic lethal interactions found in isogenic cell lines provide a basis for exploration in cancer cell lines, which more closely mimic the complex genotypes and biology present in patient tumors. Indeed, a global comparison of results from our screen and those found through cancer cell line screens indicated substantial overlap (Fig. 2A). Therefore, we tested the hypothesis that MYC is a predictive biomarker




Figure 5. MYC expression is correlated with dasatinib sensitivity in cancer cell lines and *in vivo*. **A**, relationship between dasatinib sensitivity as determined in this study and published MYC gene expression data across 664 cancer cell lines (2). An AUC < 3 is used to define sensitive cell lines. **B** and **C**, relationship between dasatinib sensitivity and MYC expression as assessed through RNAseq (**B**) and reverse-phase protein array (RPPA; **C**) data from breast cancer cell lines published in ref. 54. **D**, MYC protein levels assessed by Western blot analysis across established breast cancer cell lines. **E**, relative viability of breast cancer cell lines across a range of concentrations of dasatinib. **F**, percentage change in tumor volume of human cell lines xenografted into mice and treated daily with the indicated concentration of dasatinib via oral gavage. A minimum of 5 mice were used in each group. n.s., not significant.

for cancer cell lines that are sensitive to dasatinib. We performed high-throughput cell line sensitivity screening of dasatinib against a panel of 664 cancer cell lines spanning a variety of tumor types (Supplementary Table S4; see Methods). As controls, we verified that CML cell lines harboring *BCR-ABL* fusions were specifically sensitive to dasatinib ($P = 2 \times 10^{-9}$; Supplementary Fig. S5A and S5B). Integration of these data with previously published gene expression data (2) revealed that sensitive cell lines had higher MYC expression at the mRNA level ($P = 5 \times 10^{-4}$; Fig. 5A). In contrast, cell lines with low levels of MYC expression (relative expression <10) were >90% likely to be drug resistant, suggesting that at least a basal level of MYC expression is required for sensitivity (9 sensitive vs. 83 resistant; Fig. 5A). However, this relationship was highly dependent on the tissue of origin (Supplementary Fig. S5C) and we therefore sought to investigate this link specifically in breast cancer. Integration of drug sensitivity with focused molecular annotations of breast cancer cell lines (54) revealed a significant relationship between sensitivity and MYC mRNA and protein levels ($P = 0.0089$ and $P = 0.001$, respectively; Fig. 5B and C). Next, we selected three MYC^{high} cancer cell lines (SUM149, MDA-MB-231, and HCC1143) and two MYC^{low} lines (T47D and HCC1428) for

further interrogation, confirming their MYC levels (Fig. 5D) and MYC dependence as assessed through siRNA-mediated knockdown (Supplementary Fig. S6A). We found increased sensitivity to dasatinib in MYC^{high} cancer cell lines (IC_{50} , >100 nmol/L for MYC^{low} and <100 nmol/L for MYC^{high}; Fig. 5E). To investigate whether dasatinib can inhibit breast tumor growth *in vivo*, xenografts of MDA-MB-231 and HCC1428 were generated in nude mice and treated daily with dasatinib or vehicle administered orally for 15 days. Tumor volume was significantly reduced in MYC^{high}, MDA-MB-231 xenografts ($P = 0.01$) but not in the MYC^{low}, HCC1428-derived tumors (Fig. 5F). These data corroborate isogenic cell line responses and show that MYC levels predict dasatinib sensitivity in cancer cell lines *in vitro* and *in vivo*.

Dasatinib Synthetic Lethality Is through LYN Inhibition in MYC^{high} Breast Cancers

We next sought to understand the mechanisms by which breast cancer cells with high MYC expression respond to dasatinib. Dasatinib has been shown to bind up to 38 kinases with high affinity (55), and we reasoned that the molecular target of dasatinib might be selectively upregulated in a




Figure 6. Dependence on LYN mediates synthetic lethality between MYC and dasatinib. **A**, peptides enriched through a dasatinib-bead based affinity purification followed by quantitative mass spectrometry to identify bound peptides. Peptides representing kinases 2-fold more abundant in MCF10A^{MYC} cells are highlighted. **B**, validation via Western blot analysis of LYN, p-LYN (Y416), and MYC levels in MCF10A^{PURO} cells and MCF10A^{MYC} cells treated with dasatinib for 18 hours at indicated concentrations (nmol/L). **C**, Western blot analysis measurement of MYC, LYN, p-LYN, and SRC levels in five characterized breast cancer cell lines. **D**, relative viability after siRNA-mediated knockdown of LYN compared with nontargeting (NT), scrambled control in five breast cancer cell lines. **E**, relative viability of dasatinib-sensitive breast cancer cell lines overexpressing GFP control, LYN, and LYN T319I constructs after treatment with 1 μmol/L dasatinib compared with DMSO.

MYC-dependent manner. To elucidate upregulated drug targets, we used a proteomic approach wherein immobilized dasatinib is used to affinity purify proteins that bind the drug that are subsequently identified using quantitative mass spectrometry (56). Using this approach, we identified multiple unique peptides for the SRC-family tyrosine kinase LYN that were selectively bound and enriched in MCF10A^{MYC} cells compared with control cells (Fig. 6A and Supplementary Table S5). LYN is a direct target of dasatinib (55) and is important for B-cell activation and has been shown to be active in prostate and breast cancers (57). Immunoblot confirmed that LYN is upregulated, LYN activated by auto-phosphorylation of Y416 is increased in a MYC-dependent manner, and that LYN activation is inhibited upon drug treatment (Fig. 6B). Mirroring the changes found in isogenic cells, both total and phospho-LYN were strongly linked to MYC levels across our breast cancer cell lines

(Fig. 6C). Interestingly, SRC, a canonical target of dasatinib and known oncogene, was found to be expressed at higher levels in cell lines that were drug resistant and MYC^{low} (T47D and HCC1428), suggesting that it does not play a role in the response to dasatinib in breast cancer (Fig. 6C). We hypothesized that in MYC^{high} breast cancer cell lines LYN is necessary for cell viability and its inhibition is the basis for dasatinib sensitivity. Indeed, siRNA-mediated knockdown of LYN significantly inhibited the proliferation of all three MYC^{high} but not MYC^{low} cell lines (Fig. 6D and Supplementary Fig. S6B and S6C), and expression of a dasatinib-resistant gatekeeper mutant of LYN (T319I) significantly rescued viability of all three MYC^{high} lines when treated with dasatinib compared with GFP control (Fig. 6E and Supplementary Fig. S6D; ref. 58). Together, these data indicate that MYC^{high} breast cancer cells require LYN, and their sensitivity to dasatinib is mediated by a LYN-dependent mechanism.




Figure 7. *MYC* and *LYN* are coexpressed and have interdependent clinical outcomes. **A**, coexpression of *MYC* and *LYN* across 789 cancer cell lines, data from ref. 2. Groups of cell lines are binned by *MYC* expression. Expression of *MYC* and *LYN* across patients in the breast TCGA (23) separated on the basis of patient PAM50 subtype (**B**) and the number of positively stained molecular receptors (ER, PR, or HER2; **C**). All expression values are relative units. **D** and **E**, the Kaplan-Meier relapse-free survival (RFS) curves of I-SPY 1 patients stratified by *LYN* expression levels (**D**) patient subset with highest tertile of *MYC* expression levels ($n = 50$). **E**, patient subset with lowest tertile of *MYC* expression levels ($n = 99$).

MYC and LYN Are Strongly Linked and Have Interdependent Clinical Outcomes

This synthetic lethal interaction suggests that patient tumors harboring high levels of *MYC* may respond to dasatinib through inhibition of *LYN*. Indeed, expression of *MYC* and *LYN* transcripts were tightly linked across a panel of 807 cancer cell lines from diverse origins (Fig. 7A), and correlated in breast cancer cell lines ($r = 0.53$; $P = 2 \times 10^{-4}$; Supplementary Fig. S7). In patients, both *MYC* and *LYN* were significantly coexpressed across 919 patients in the breast TCGA ($r = 0.23$; $P = 1 \times 10^{-12}$) and highest in the basal subtype and TNBC patient population (Fig. 7B and C; ref. 23). To interrogate whether the combined activity of *MYC* and *LYN* could influence clinical outcomes, we investigated data from the I-SPY1 breast cancer clinical trial ($n = 149$ patients) where we stratified patients based on their tertile of expression of *MYC* and *LYN*. In patients with *MYC*^{high} tumors, those with higher expression of *LYN* were more likely to relapse and had a decreased survival (Fig. 7D; $P = 0.017$, log rank test). In contrast, high expression of *LYN* did not correlate with outcome

in *MYC*^{low} patients (Fig. 7E). These data suggest that *MYC* hyperactivation leads to an increased dependency on *LYN* in human breast cancers.

DISCUSSION

We present a quantitative platform and dataset for mapping genotype-specific responses to clinically relevant inhibitors using an isogenic panel of cell lines harboring distinct genetic events. We envision that this dataset can help shape systems pharmacology-based approaches for cancer therapy. As opposed to prior barcoded-based approaches that were unable to capture both resistance and sensitivity (10, 11, 18), the quantitative nature of our dataset allowed us to perform several key comparisons. We uncovered a strong overlap of drug response biomarkers through comparison with previous large-scale cancer cell line screening efforts as well as focused comparison with the AKT inhibitor MK-2206 and dasatinib. Our dataset is strongly predictive of cancer cell line drug sensitivities and indicates that engineered isogenic cell lines can accurately model the biology

of mutations present in genetically complex tumor samples. The proposed platform has several distinct advantages over correlative screening approaches in cancer cell lines. Although cancer cell lines represent the natural heterogeneity of clinical cancer cases, effective screening requires a panel of cell lines harboring each mutation of interest. For rare mutations, gathering sufficient lines may be prohibitive or impossible. In addition, the presence of many mutations in any single cell line makes statistical association difficult. Finally, a known limitation of current synthetic lethal screening platforms using cancer cell line collections is the inability to accurately model cellular contexts specific to particular disease types (6). Although we have focused on breast cancer, future work may develop an expanded and tailored isogenic cell line encyclopedia that encompasses the majority of recurrent oncogenic mutations, amplifications, and deletions found in a particular tumor type. Integrative analysis of drug responses, pathway alterations, and emerging dependencies in these lines will likely illuminate previously unexplored therapeutic avenues.

This chemical-genetic interaction map revealed a number of novel connections and provides a valuable dataset for the exploration of therapeutic responses for a variety of cancer genes. As proof-of-concept that the interaction map can predict biologically relevant and clinically actionable responses, we investigated dependencies induced by MYC. Analysis indicated that MYC could drive resistance to multiple PI3K-AKT-mTOR pathway inhibitors. As many of these inhibitors are being explored in the clinic, this finding provides a possible route to both innate and acquired resistance to these drugs in patients. The top synthetic lethal hit with MYC was dasatinib, which has previously been found to be effective in basal breast cancer cell lines *in vitro* (59), a subtype often expressing high levels of MYC (33). Here, we show that it can also be effective against breast tumor xenografts harboring high MYC levels *in vivo*. In addition, our results indicate that MYC-driven dasatinib sensitivity is likely through LYN inhibition. This connection is intriguing, because MYC has previously been suggested to operate both upstream and downstream of SRC-family kinases, including LYN, in other tumor types (60, 61). Like MYC, LYN has also been shown to be preferentially active in basal breast cancers (62, 63). Interestingly, dasatinib was also found to be synthetic lethal with *CCND3* ($S = -2.6$), which encodes cyclin D3, a component of the CDK4/6 complex. Because CDK genes have been shown to be synthetic lethal with MYC activation (17, 33, 64), one possibility is that dasatinib may be more effective in cells with enhanced cell-cycle progression through upregulation of either *CCND3* or MYC. Further studies will be necessary to determine the exact molecular mechanisms by which MYC-expressing cells become dependent on LYN. However, the fact that MYC and LYN are highly coexpressed in patients and combine to influence outcomes provides strong evidence of their functional relationship.

Limited therapeutic options currently exist for patients with TNBC. This work indicates that the approved drug dasatinib may be an immediately applicable and efficacious treatment for this challenging subset of breast cancer patients. Previous trials of dasatinib in TNBC patient populations have had limited response rates (65, 66) that may be enhanced in the future by using MYC and LYN expression

as biomarkers for patient selection. As dasatinib is FDA-approved, it provides an example of how chemical-genetic interaction maps can provide valuable insights that can ultimately be used to repurpose existing drugs for new clinical trials, thus accelerating therapeutic development. The ability to systematically map molecular drivers of drug responses revealed a plethora of unexpected but actionable connections and provides a blueprint for new systems approaches for precision medicine.

METHODS

MCF10A Cell Line Generation and Screening

MCF10A parental cell lines were grown according to published protocols (38). Derivative isogenic cell lines were generated through stable infection using viral infection of cell pools using the indicated vectors (Supplementary Table S1). Control MCF10A cell lines were generated by expressing empty vectors conferring puromycin, or blasticidin gene resistance as appropriate. Proliferation was measured by staining with Hoescht nuclear dye and cell (nuclear) number counted using a Thermo CellInsight High Content microscope. The parental cell line was first screened against all 90 compounds (Selleckchem) to determine concentration-response curves and approximate IC_{50} concentrations (Supplementary Table S2). The maximum concentration assayed for any drug was approximately 20 $\mu\text{mol/L}$. Each line was independently screened by plating 1,000 cells per well in 384-well plates for 24 hours and then exposed to each drug at IC_{50} concentration for 72 hours using a minimum of eight replicates. Statistical scoring is described in detail in the Supplementary Methods.

Viability and Apoptosis Assays

Cell viability was determined using the CellTiter-Glo cell viability assay per the manufacturer's instructions (Promega). Apoptosis was measured through cell fixation and staining with early-apoptosis marker Annexin V and quantified through FACS using standard protocols.

High-Throughput Cancer Cell Line Screening

Cancer cell lines were obtained from the Broad Institute's Biological Samples Platform and are a subset of the Cancer Cell Line Encyclopedia's human cancer cell lines (2). Cell lines were grown in their specified medium at 37°C/5% CO₂ and plated into duplicate in 1,536-well assay plates at a density of 500 cells per well in 6 μL of total volume. The cells were incubated overnight and then treated with dasatinib in a 16-point, 2-fold concentration range for 72 hours. ATP levels were measured using the CellTiter-Glo as a surrogate for cell viability. Cellular responses to compounds were based on a normalized area under the dose-response curve (AUC) as described previously (2). Sensitive cell lines are annotated as those with $AUC < 3$.

Cell Culture, siRNA Transfection, and Immunoblotting

MDA-MB-231 cells were obtained from the American Type Culture Collection (ATCC) and were propagated in DMEM containing 10% FBS. T47D, HCC1143, and HCC1428 cells were obtained from the ATCC and propagated in RPMI-1640 containing 10% FBS. SUM149 cells were obtained from the laboratory of Dr. Joe Gray (Oregon Health Sciences University, Portland, OR) and propagated in F-12 with 5% FBS, insulin, and hydrocortisone. No additional cell line authentication was conducted by the authors. The following antibodies were used for immunoblot analyses: MYC and MCL-1 (Abcam), β -actin and BCL-XL (Santa Cruz Biotechnology, Inc.), PARP, SRC, LYN, and p-LYN (Cell Signaling Technology), and BIM (Assay Designs).

Xenograft Analysis

Animal work was conducted in accordance with protocols approved by the Institutional Care and Use Committee for animal research at the University of California, San Francisco (San Francisco, CA). Nude mice (BALB/c nude/nude) were subcutaneously injected with 1.5×10^6 MDA-MB-231 cells or 6×10^6 HCC1428 cells mixed 1:1 with Basement Membrane Matrix (BD Biosciences). Initial tumor dimensions were monitored three times weekly and the treatment was initiated when tumor volume reached about 80 mm³. Once animals reached the indicated tumor volume, they were randomly placed into control or treatment groups. Animals were treated daily for 14 days via oral gavage with 50 mg/kg dasatinib (Sprycel) tablets from the UCSF pharmacy that were crushed and dissolved in water. Tumor volume was calculated daily from two diameter measurements using calipers: one along the anterior–posterior axis and the other along the lateral–medial axis. Percentage change for tumor growth is based on volumes calculated from size on day 1 of treatment compared with day 15.

Statistical Parameters

All *P* values are based on a two-tailed Student *t* test unless otherwise noted. All error bars are standard deviation unless otherwise noted.

Disclosure of Potential Conflicts of Interest

A. Sorrentino is a senior scientist at Exiqon A/S. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: A.Y. Zhou, D. Horiuchi, J.D. Gordan, F. McCormick, A. Goga, S. Bandyopadhyay

Development of methodology: M.M. Martins, A. Corella, J.D. Gordan, R.S. Levin, J. Johnson, A. Sorrentino, P.A. Clemons, K.M. Shokat, S. Bandyopadhyay

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M.M. Martins, A.Y. Zhou, A. Corella, D. Horiuchi, T. Rakshandehroo, J.D. Gordan, R.S. Levin, J. Johnson, J. Jascur, A. Sorrentino, J. Cheah, N.J. Krogan, F. McCormick

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M.M. Martins, A.Y. Zhou, A. Corella, D. Horiuchi, C. Yau, J.D. Gordan, R.S. Levin, P.A. Clemons, A.F. Shamji, S.L. Schreiber, N.J. Krogan, S. Bandyopadhyay

Writing, review, and/or revision of the manuscript: A.Y. Zhou, J.D. Gordan, R.S. Levin, A.F. Shamji, N.J. Krogan, F. McCormick, A. Goga, S. Bandyopadhyay

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.Y. Zhou, J. Jascur, M. Shales, S. Bandyopadhyay

Study supervision: A. Goga, S. Bandyopadhyay

Acknowledgments

The authors acknowledge members of the McCormick laboratory for advice and reagents; Mercedes Joaquin for assistance with mouse experiments; and Susan Samson at the UCSF Breast Oncology Program Advocacy Core for helpful discussions.

Grant Support

This work was supported by Martha and Bruce Atwater (to S. Bandyopadhyay and A. Goga), a UCSF Breast Oncology SPORE development award (to S. Bandyopadhyay and A. Goga), NCI U01CA168370 (to S. Bandyopadhyay and F. McCormick), NIGMS R01GM107671 (to S. Bandyopadhyay and N.J. Krogan), NIH T32 Postdoctoral Training Award 5T32CA108462-10 (to A.Y. Zhou), NCI 5R01CA136717 (to A. Goga), the Leukemia and Lymphoma Scholar Award (to A. Goga), and Congressionally Directed Medical Research Programs (CDMRP) Award W81XWH-12-1-0272 (to A. Goga).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 28, 2014; revised December 9, 2014; accepted December 9, 2014; published OnlineFirst December 12, 2014.

REFERENCES

1. Yaffe MB. The scientific drunk and the lamppost: massive sequencing efforts in cancer discovery and treatment. *Sci Signal* 2013;6:pe13.
2. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* 2012;483:603–7.
3. Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. *Cell* 2013;154:1151–61.
4. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. *Nature* 2012;483:570–5.
5. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. *Cell* 2011;145:30–8.
6. Nijman SM, Friend SH. Cancer. Potential of the synthetic lethality principle. *Science* 2013;342:809–11.
7. Bandyopadhyay S, Mehta M, Kuo D, Sung MK, Chuang R, Jaehng EJ, et al. Rewiring of genetic networks in response to DNA damage. *Science* 2010;330:1385–9.
8. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, et al. The genetic landscape of a cell. *Science* 2010;327:425–31.
9. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. *Cancer Cell* 2013;23:121–8.
10. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. *Cell* 2009;137:835–48.
11. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. *Cell* 2009;137:821–34.
12. Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne PH, Kuznetsov H, et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. *Cell Res* 2012;22:1227–45.
13. Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. *Chem Biol* 2008;15:234–45.
14. Wang Y, Ngo VN, Marani M, Yang Y, Wright G, Staudt LM, et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. *Oncogene* 2010;29:4658–70.
15. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature* 2009;462:108–12.
16. Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, et al. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. *Clin Cancer Res* 2013;19:5413–22.
17. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. *Nat Med* 2007;13:820–7.
18. Muellner MK, Uras IZ, Gapp BV, Kerzendorfer C, Smida M, Lechtermann H, et al. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. *Nat Chem Biol* 2011;7:787–93.
19. Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, et al. BRAF V600E is a determinant of sensitivity to proteasome inhibitors. *Mol Cancer Ther* 2013;12:2950–61.

20. Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, et al. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the “basal” breast cancer subgroup. *PLoS One* 2009;4:e4710.
21. Chandriani S, Frengen E, Cowling VH, Pendergrass SA, Perou CM, Whitfield ML, et al. A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. *PLoS ONE* 2009;4:e6693.
22. Gatz ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, et al. A pathway-based classification of human breast cancer. *Proc Natl Acad Sci U S A* 2010;107:6994–9.
23. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. *Nature* 2012;490:61–70.
24. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. *Cell* 1984;38:627–37.
25. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes *in vivo*. *Cell* 1987;49:465–75.
26. Podsypanina K, Politi K, Beverly LJ, Varmus HE. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. *Proc Natl Acad Sci U S A* 2008;105:5242–7.
27. D’Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. *Nat Med* 2001;7:235–9.
28. Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. *Oncogene* 1998;17:2463–72.
29. Soucek L, Jucker R, Panacchia L, Ricordy R, Tato F, Nasi S. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. *Cancer Res* 2002;62:3507–10.
30. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. *Science* 2002;297:102–4.
31. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. *Cell* 2011;146:904–17.
32. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. *Proc Natl Acad Sci U S A* 2012;109:19408–13.
33. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. *J Exp Med* 2012;209:679–96.
34. Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. *Science* 2012;335:348–53.
35. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. *Proc Natl Acad Sci U S A* 2012;109:9545–50.
36. Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. *Proc Natl Acad Sci U S A* 2010;107:13836–41.
37. Cermelli S, Jang IS, Bernard B, Grandori C. Synthetic lethal screens as a means to understand and treat MYC-driven cancers. *Cold Spring Harb Perspect Med* 2014;4:a014209.
38. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. *Cell* 2002;111:29–40.
39. Collins SR, Roguev A, Krogan NJ. Quantitative genetic interaction mapping using the E-MAP approach. *Methods Enzymol* 2010;470:205–31.
40. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. *Nature* 2012;486:532–6.
41. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science* 2007;316:1039–43.
42. Vazquez-Martin A, Cufi S, Oliveras-Ferraras C, Torres-Garcia VZ, Corominas-Faja B, Cuyas E, et al. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. *Sci Rep* 2013;3:2560.
43. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. *Proc Natl Acad Sci U S A* 2012;109:E2127–33.
44. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. *Cancer Res* 2009;69:4286–93.
45. Lin CJ, Nasr Z, Premrsirrut PK, Porco JA Jr, Hippo Y, Lowe SW, et al. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. *Cell Rep* 2012;1:325–33.
46. Liu L, Ulbrich J, Muller J, Wustefeld T, Aeberhard L, Kress TR, et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. *Nature* 2012;483:608–12.
47. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. *Nat Med* 2011;17:1116–20.
48. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. *Proc Natl Acad Sci U S A* 2012;109:2724–9.
49. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. *J Biol Chem* 2003;278:51606–12.
50. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. *Cell* 1992;69:119–28.
51. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. *J Neurochem* 2008;104:1433–9.
52. Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, et al. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. *PLoS ONE* 2010;5:e9201.
53. Yaswen P, Stampfer MR. Molecular changes accompanying senescence and immortalization of cultured human mammary epithelial cells. *Int J Biochem Cell Biol* 2002;34:1382–94.
54. Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, et al. Modeling precision treatment of breast cancer. *Genome Biol* 2013;14:R110.
55. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. *Nat Biotechnol* 2011;29:1046–51.
56. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. *Nat Biotechnol* 2007;25:1035–44.
57. Ingley E. Functions of the Lyn tyrosine kinase in health and disease. *Cell Commun Signal* 2012;10:21.
58. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. *Nat Struct Mol Biol* 2008;15:1109–18.
59. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyan N, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing *in vitro*. *Breast Cancer Res Treat* 2007;105:319–26.
60. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. *Proc Natl Acad Sci U S A* 2001;98:7319–24.

61. Seitz V, Butzhammer P, Hirsch B, Hecht J, Gutgemann I, Ehlers A, et al. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. *PLoS ONE* 2011;6:e26837.
62. Croucher DR, Hochgrafe F, Zhang L, Liu L, Lyons RJ, Rickwood D, et al. Involvement of Lyn and the atypical kinase Sgk269/PEAK1 in a basal breast cancer signaling pathway. *Cancer Res* 2013;73:1969-80.
63. Hochgrafe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, et al. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. *Cancer Res* 2010;70:9391-401.
64. Horiuchi D, Huskey NE, Kusdra L, Wohlbold L, Merrick KA, Zhang C, et al. Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways. *Proc Natl Acad Sci U S A* 2012;109:E1019-27.
65. Finn RS, Bengala C, Ibrahim N, Roche H, Sparano J, Strauss LC, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. *Clin Cancer Res* 2011;17:6905-13.
66. Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, et al. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. *Mol Cancer Ther* 2010;9:1120-7.

CANCER DISCOVERY

Linking Tumor Mutations to Drug Responses via a Quantitative Chemical–Genetic Interaction Map

Maria M. Martins, Alicia Y. Zhou, Alexandra Corella, et al.

Cancer Discovery 2015;5:154-167. Published OnlineFirst December 12, 2014.

Updated version	Access the most recent version of this article at: doi: 10.1158/2159-8290.CD-14-0552
Supplementary Material	Access the most recent supplemental material at: http://cancerdiscovery.aacrjournals.org/content/suppl/2014/12/12/2159-8290.CD-14-0552.DC1.html

Cited Articles	This article cites by 65 articles, 26 of which you can access for free at: http://cancerdiscovery.aacrjournals.org/content/5/2/154.full.html#ref-list-1
-----------------------	---

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org .